...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
【24h】

Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study

机译：在转移性肾细胞癌患者中的其他有针对性疗法后，孙尼替尼重新检查：单中心，回顾性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundSunitinib is still one of the standard therapies in metastatic renal cell carcinoma (mRCC). Despite the benefit of sunitinib resistance will develop in the majority of patients. Most of them receive multiple sequential therapies during the course of disease.ObjectivesTo retrospectively investigate the efficacy and safety of rechallenged sunitinib in third or later line settings.Patients and MethodsTwenty-one mRCC patients were identified who received rechallenged sunitinib between March 2010 and April 2018. Patients received sunitinib in first or second line, then other tyrosine kinase and/or mTOR inhibitors were applied, then sunitinib was rechallenged. Patients' characteristics, tolerability, treatment modalities, and treatment outcomes were recorded. The primary end-point was progression-free survival (PFS) of rechallenged sunitinib.ResultsMedian age of patients was 62years at the start of sunitinib rechallenge. Sixty-seven percent of patients were male. All patients had prior nephrectomy. Upon rechallenge 4 patients achieved partial response and 12 stable disease. The median PFS of first sunitinib treatment was 22 (95% CI 17-26) months and for rechallenged sunitinib 14 (95% CI 6-20) months. No increased severity of prior toxicity or new adverse events was reported during rechallenged sunitinib. The median overall survival (OS) from the start of first sunitinib was 67 (95% CI 46-76) months. Multivariate Cox regression analysis revealed that younger age ( 2years) first sunitinib treatment (HR=0.28; 95% CI 0.09-0.93; p=0.038) were independent markers of longer OS.ConclusionSunitinib rechallenge is a feasible and tolerable option with clinical benefit in selected mRCC patients.
机译：BackgroundSunitinib仍然是转移性肾细胞癌（MRCC）的标准疗法之一。尽管户外抵抗的兴趣将在大多数患者中发展。其中大多数在疾病过程中受到多个顺序疗法。objectivesto回顾性地研究了第三或后期线路设置的重新启动的桑顿的疗效和安全性。在2010年3月至2018年3月期间接受了Reclalgenged Sunitinib的患者和方法，患者和方法。患者在第一或第二线中接受Sunitinib，然后施加其他酪氨酸激酶和/或MTOR抑制剂，然后孙氨醇被重新接受。记录患者的特征，耐受性，治疗方式和治疗结果。主要终点是Rechallenged Sunitinib的无进展生存期六十七名患者是男性。所有患者患有先前的肾切除术。重新开始4例患者实现部分反应和12例稳定疾病。第一次舒替尼治疗的中位数为22个（95％CI 17-26）个月，为瑞伊替尼14个月（95％CI 6-20）个月。在Rechallenged Sunitinib期间报道了未毒性或新的不良事件的严重程度。第一瑞替尼开始的中位数生存（OS）为67（95％CI 46-76）个月。多元Cox回归分析显示，较年轻的年龄（2年）首次晒碱治疗（HR = 0.28; 95％CI 0.09-0.93; p = 0.038）是较长的OS.Conclusionsunitinib的独立标记是选择的可行性和可耐受的选择MRCC患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号